Radiation Recall with Anticancer Agents

por Burris, Howard A., Hurtig, Jane
Publicado 2010

Cardio-Oncology: Stronger Together

por Kovacs, Richard J., Burris, Howard A.
Publicado 2019

Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin

por Sager, Philip T, Balser, Barbara, Wolfson, Julie, Nichols, Jean, Pilot, Richard, Jones, Suzanne, Burris, Howard A
Publicado 2015

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer

por Laille, Eric, Patel, Manish, Jones, Suzanne F., Burris, Howard A., Infante, Jeffrey, Lemech, Charlotte, Liu, Liangang, Arkenau, Hendrik‐Tobias
Publicado 2015

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer

por Sobrero, Alberto, Lenz, Heinz‐Josef, Eng, Cathy, Scheithauer, Werner, Middleton, Gary, Chen, Wenfeng, Esser, Regina, Nippgen, Johannes, Burris, Howard
Publicado 2020

A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States

por Brown, Jacqueline, Scardo, Savannah, Method, Michael, Schlauch, Dan, Misch, Amanda, Picard, Shaita, Hamilton, Erika, Jones, Suzanne, Burris, Howard, Spigel, David
Publicado 2022

Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer

por Burris, Howard, Stephenson, Joe, Otterson, Gregory A., Stein, Mark, McGreivy, Jesse, Sun, Yu-Nien, Ingram, Megan, Ye, Yining, Schwartzberg, Lee S.
Publicado 2011

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors

por Burris, Howard, Ansell, Stephen, Neumanitis, John, Weiss, Geoffrey, Sikic, Branimir, Northfelt, Donald, Pilja, Lana, Davis, Thomas, Yellin, Michael, Keler, Tibor, Bullock, Timothy
Publicado 2013

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors

por Ansell, Stephen, Northfelt, Donald, Flinn, Ian, Burris, Howard, Dinner, Shira, Villalobos, Victor, Sikic, Branimir, Pilja, Lana, Yellin, Michael, Keler, Tibor, Davis, Thomas
Publicado 2013

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribocic...

por Verma, Sunil, O’Shaughnessy, Joyce, Burris, Howard A., Campone, Mario, Alba, Emilio, Chandiwana, David, Dalal, Anand A., Sutradhar, Santosh, Monaco, Mauricio, Janni, Wolfgang
Publicado 2018

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

por LoRusso, Patricia M., Infante, Jeffrey R., Kim, Kevin B., Burris, Howard A., Curt, Gregory, Emeribe, Ugochi, Clemett, Delyth, Tomkinson, Helen K., Cohen, Roger B.
Publicado 2017

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors

por Infante, Jeffrey R., Cohen, Roger B., Kim, Kevin B., Burris, Howard A., Curt, Gregory, Emeribe, Ugochi, Clemett, Delyth, Tomkinson, Helen K., LoRusso, Patricia M.
Publicado 2017

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors

por Infante, Jeffrey R., Cohen, Roger B., Kim, Kevin B., Burris, Howard A., Curt, Gregory, Emeribe, Ugochi, Clemett, Delyth, Tomkinson, Helen K., LoRusso, Patricia M.
Publicado 2017

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors

por Pant, Shubham, Burris, Howard A., Moore, Kathleen, Bendell, Johanna C., Kurkjian, Carla, Jones, Suzanne F., Moreno, Ofir, Kuhn, John G., McMeekin, Scott, Infante, Jeffrey R.
Publicado 2013

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohor...

por Burris, Howard A, Bakewell, Suzanne, Bendell, Johanna C, Infante, Jeffrey, Jones, Suzanne F, Spigel, David R, Weiss, Glen J, Ramanathan, Ramesh K, Ogden, Angela, Von Hoff, Daniel
Publicado 2017

Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings

por Sturgill, Emma G, Misch, Amanda, Jones, Carissa C, Luckett, Daniel, Fu, Xiaotong, Schlauch, Dan, Jones, Suzanne F, Burris, Howard A, Spigel, David R, McKenzie, Andrew J
Publicado 2022

Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

por Bendell, Johanna C, Patel, Manish R, Infante, Jeffrey R, Kurkjian, Carla D, Jones, Suzanne F, Pant, Shubham, Burris, Howard A, Moreno, Ofir, Esquibel, Vanessa, Levin, Wendy, Moore, Kathleen N
Publicado 2015

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors

por Shapiro, Geoffrey I., Kristeleit, Rebecca S., Burris, Howard A., LoRusso, Patricia, Patel, Manish R., Drew, Yvette, Giordano, Heidi, Maloney, Lara, Watkins, Simon, Goble, Sandra, Jaw‐Tsai, Sarah, Xiao, Jim J.
Publicado 2018

A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

por Papadopoulos, Kyriakos P., Burris, Howard A., Gordon, Michael, Lee, Peter, Sausville, Edward A., Rosen, Peter J., Patnaik, Amita, Cutler, Richard E., Wang, Zhengping, Lee, Susan, Jones, Suzanne F., Infante, Jeffery R.
Publicado 2013

Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours

por Johnson, Melissa L., Wang, Judy S., Falchook, Gerald, Greenlees, Carol, Jones, Suzanne, Strickland, Donald, Fabbri, Giulia, Kennedy, Caroline, Elizabeth Pease, J., Sainsbury, Liz, MacDonald, Alexander, Schalkwijk, Stein, Szekeres, Philip, Cosaert, Jan, Burris, Howard
Publicado 2023